Министерство науки и высшего образования Российской Федерации Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского» Федеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Министерство науки и высшего образования Российской Федерации Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского» Федеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации
BackgroundPurine nucleoside phosphorylase (PNP, EC 2.4.2.1) plays a leading role in the assimilation of nucleosides and nucleotides by the cell, as well as in maintaining the immune status of the organism. Patients with PNP deficiency are highly susceptible to various infections, in view of the fact that the decreased activity of PNP is closely related to the insufficiency of cellular immunity.ObjectivesStudy of the possibility of using the level antibodies to purine nucleoside phosphorylase as an additional marker of infectious complications in patients with systemic lupus erythematosus (SLE).MethodsThe study included 60 patients with SLE (women – 91.7%, mean age 36.32±15.27 years, average duration of the disease 7.96±7.35 years) with different clinical manifestations (SLEDAI activity 8.93±5,74, ECLAM activity 5.30±2.79, damage index SLICC/ACR 1.95±1.71). Antibodies to PNP (anti-PNP) were determined in our indirect ELISA test using the immobilised form of the enzyme as an antigenic matrix.The presence of infectious complications in SLE patients was assessed by characteristic clinical manifestations and was considered to be confirmed when the causative agent was recognised and/or the serological analyses are positive. Infections were diagnosed in 38.3% of patients, the most frequent localization was the urinary system (n=12; 52.2%) and female genitalia (n=5; 21.7%).ResultsIn the presence anti-PNP in the blood serum of patients with SLE we have often noted infectious complications (p=0.025, criterion χ2) and less often lung damage (p=0.17) (when compared with a group of patients with SLE seronegative for the presence of anti-PNP).Statistically significant differences (Mann-Whitney U-criterion) were detected only for pyuria (p<0.0005), C-reactive protein level (p=0.048) and the number of ceruloplasmin (p=0.008), while comparing the groups of SLE patients with the presence of infectious complications and without it; differences in the level of antibodies to CP (p=0.052) did not reach statistical significance. Other clinical and laboratory parameters do not have statistically significant differences between the two sessions. This fact complicates the recognition and differential diagnosis of infectious complications in SLE significantly.The analysis of the characteristic curve of antibodies to PNP in the diagnosis of infectious pathology in SLE shows limited possibilities for using this parameter. The square under the curve was 0.687 (95% confidence interval 0.523–0.804, p=0.008), the separation point was 0.386 U/ml with a sensitivity of 55% and a specificity of 83%.Taking into account that the typical clinical manifestations of infection with SLE can be erased as a result of the actual activity of SLE, and due to the use of immunosuppressive drugs, timely diagnosis and treatment become especially relevant. This study indicates the possibility of using the level of antibodies to PNP as an additional marker of infection, but the balance between specificity and sensitivity of this test does not allow to recommend it as ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.